Prognostic implications of PD-L1 expression in patients with angiosarcoma

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Research

Background:

• Metastatic angiosarcoma is an aggressive cancer with limited treatment options.
• The prognostic value of programmed death ligand-1 (PD-L1) expression in angiosarcoma remains unclear.

Purpose of the Study:

• To investigate the feasibility of PD-L1 expression as a prognostic biomarker in metastatic angiosarcoma.
• To determine the association between PD-L1 status and patient survival outcomes.

Main Methods:

• Retrospective analysis of PD-L1 expression in 70 metastatic angiosarcoma patients diagnosed between 2005 and 2019.
• Correlation of PD-L1 expression status with progression-free survival (PFS) and overall survival (OS).

Main Results:

• PD-L1 expression was detected in 13% of patients.
• PD-L1-negative patients exhibited significantly longer median PFS (4.9 vs 1.6 months) and OS (10.9 vs 5.4 months) compared to PD-L1-positive patients.
• PD-L1 status was a significant independent prognostic factor for OS.

Conclusions:

• PD-L1 expression is associated with poorer survival outcomes in metastatic angiosarcoma.
• PD-L1 status serves as an independent prognostic biomarker for overall survival in this patient population.